Ultragenyx Pharmaceutical
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations sp...
Latest News
5 days ago · seekingalpha.com
Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating HoldI initiate coverage of Ultragenyx Pharmaceutical with a Hold rating and $18 price target, citing a credible valuation floor but limited near-term catalysts. Two major late-stage pipeline failures have reset investor sentiment, and I see few meaningful catalysts over the next 12 months. RARE's legacy business is stable, but new gene therapies face payer pushback, tiny patient pools, and unproven durability, posing long-term risks.
5 days ago · globenewswire.com
Ultragenyx to Participate at Investor Conferences in LondonNOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in upcoming investor conferences.
13 days ago · seekingalpha.com
Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' PivotUltragenyx Pharmaceutical remains a cautious 'Hold,' as profitability targets are driven by deep R&D cuts, not robust revenue growth. RARE's Q3 revenue rose 8% Y/Y to $173M, but business remains highly concentrated in CRYSVITA, with new launches contributing minimally. Pipeline setbacks and terminated programs have forced a pivot from high-risk optionality to a leaner rare-disease commercial model.
13 days ago · seekingalpha.com
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call TranscriptUltragenyx Pharmaceutical Inc. ( RARE ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Howard Horn - Executive VP of Corporate Strategy & CFO Erik Harris - Executive VP & Chief Commercial Officer Eric Crombez - Chief Medical Officer & Executive VP Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Joon Lee Jaena Han - TD Cowen, Research Division Tazeen Ahmad - BofA Securities, Research Division Maxwell Skor - Morgan Stanley, Research Division Lydia Erdman - Goldman Sachs Group, Inc., Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Luca Issi - RBC Capital Markets, Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C.
13 days ago · marketbeat.com
What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings CallUltragenyx Pharmaceutical NASDAQ: RARE said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, the termination of its Wilson disease program and restructuring actions intended to support GAAP profitability in 2027.
13 days ago · zacks.com
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue EstimatesUltragenyx (RARE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $1.81 per share a year ago.
13 days ago · zacks.com
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key MetricsWhile the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
13 days ago · globenewswire.com
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review Vouchers (PRVs) under agreement for combined sales price of $413 million Substantial reduction of expenses and headcount underway, expected to drive at least a 50% reduction in 2027 R&D expenses vs 2025 NOVATO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2026, announced substantial expense reductions, and reaffirmed its guidance for 2026 revenue and 2027 profitability.
20 days ago · globenewswire.com
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate UpdateNOVATO, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m.
20 days ago · prnewswire.com
AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New Long-Term UPLIZNA Data in IgG4-Related Disease and Real-World Evidence for KRYSTEXXA and TAVNEOS Further Highlight Amgen's Broad Portfolio and Commitment to People Living with Rare Diseases THOUSAND OAKS, Calif., Oct. 27, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to present new data across its portfolio, including in rare and other serious autoimmune diseases at the American College of Rheumatology (ACR) Convergence 2026.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove RARE